Allergy Shots Reducing Reliance on Daily Medications to Enhance Overall Quality of Life for Patients: Fact.MR Report
Rockville, MD, July 18, 2024 (GLOBE NEWSWIRE) — Fact.MR, in its new research report, states that revenue from the global allergy shot market is estimated to reach US$ 1.84 billion in 2024 and advance further at a CAGR of 6.1% from 2024 to 2034.
With allergies becoming more prevalent due to ever-rising urbanization and environmental changes, more people are turning to allergy shots, which are turning out to be long-term treatments for relief. These injections offer personalized therapy targeting multiple allergies simultaneously and may even prevent new allergies from developing. They are favored by patients and healthcare providers alike for reducing reliance on daily medications and improving overall quality of life.
For More Insights into the Market, Request a Sample of this Report
The effectiveness of allergy shots in managing allergic asthma and potentially preventing its onset, along with their support for pet ownership and occupational health, has bolstered their appeal. As awareness grows regarding their long-term benefits, an increasing number of people are opting for allergy immunotherapy as a proactive approach to allergy management. The allergy injection market is poised for continued growth, driven by a global shift towards preventive healthcare and personalized medicine.
Key Takeaways from Market Study
- The global allergy shot market is projected to generate revenue of US$ 3.34 billion by the end of 2034.
- The market in North America is projected to hold a share of 40.3% by 2034-end.
- The East Asia market is forecasted to reach a valuation of US$ 776 million by 2034.
- By 2034, the market in Canada is evaluated to reach a size of US$ 147 million.
- Based on product type, sales of SLIT tablets are estimated to reach US$ 293.3 million in 2024.
- The retail sales segment is poised to occupy 42.2% market share in 2024.
“Allergy shots are effective in managing allergic asthma and may even prevent its onset in certain cases. Increasing awareness of the long-term benefits of allergy immunotherapy has driven more people to choose this approach to managing allergies,” says a Fact.MR analyst.
Leading Players Driving Innovation in Allergy Shots Market
Some of the prominent manufacturers of Circassia; Merck; Allergy Therapeutics; ALK-Abello; Letipharma; HollisterStier Allergy; Aimmune Therapeutics; DBV Technologies; Stallergenes Greer; HAL Allergy Group; Biomay AG. Other Prominent Players.
Advancements in Molecular Diagnostics Enabling Customized Therapy Formulations
Researchers are exploring innovative delivery methods like sublingual and oral immunotherapy as needle-free alternatives to traditional injections. These options aim to enhance accessibility and patient compliance. Personalized medicine is revolutionizing allergy treatments with advancements in molecular diagnostics, enabling precise allergen detection and tailored therapy formulations. This approach minimizes adverse effects while improving treatment efficacy.
Biotechnology firms are developing adjuvant vaccines to enhance immune responses, potentially reducing treatment duration and enhancing outcomes. Additionally, the development of recombinant allergens holds promise for safer and more standardized immunotherapy solutions. Integration of digital health technologies such as smart autoinjectors and smartphone apps for symptom tracking is enhancing treatment adherence and monitoring processes.
Get Customization on this Report for Specific Research Solutions
Allergy Shot Industry News-
In October 2023, Itulatek’s phase 3 experiment for the treatment of allergic rhino-conjunctivitis brought on by tree pollen was completed, according to ALK.
In January 2023, HollisterStier Allergy introduced Ultrafiltered Dog, their newest product innovation, to the allergy market. Patients who are sensitive to dogs respond well to the product’s diagnosis and therapy.
In October 2022, Aimmune Therapeutics and Allergy Partners, a specialized allergy practice group, partnered to provide Palforzia, an oral immunotherapy, to patients directly.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the allergy shot market for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on product (SLIT tablets, oral, injections), immunotherapy (sublingual immunotherapy, subcutaneous immunotherapy), indication (allergic rhinitis, allergic asthma, food allergy, atopic dermatitis), allergen (pollen, house dust mites, mold, animal dander, bee venom, cockroaches/insects), and distribution channel (institutional sales, retail sales), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).
Checkout More Related Studies Published by Fact.MR Research:
Pet Allergy Immune Supplements Market in 2022 were held at US$ 228 million. With 12.2% projected growth from 2023 to 2033, the market is expected to reach a valuation of US$ 800 million by the end of the forecast period.
Global OTC Cough, Cold And Allergy Medicine Market reached a valuation of US$ 36.92 Billion in 2021Y, and is likely to register a Y-o-Y growth rate of 5.0% in 2022, closing at US$ 38.96 Billion. Furthermore, across the 2022-2032
Allergy Care Market Is estimated at USD 22 Billion in 2022 and is forecast to surpass USD 40 Billion by 2032, growing at a CAGR of 6.1% from 2022 to 2032.
Allergic Rhinitis Treatment Device Market: is valued at USD 1.84 Billion in 2022. This market is expected to surpass a value of USD 2.47 Billion by end of 2032.
Allergic Rhinitis Treatment Market: size is estimated at US$ 16.03 billion in 2024 and is projected to reach a valuation of US$ 23.38 billion by the end of 2034, advancing at a CAGR of 3.8% over the next ten years.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Follow Us: LinkedIn | Twitter | Blog
CONTACT: Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 Sales Team:sales@factmr.com
